Levy J
Cancer Treat Rep. 1978 Nov;62(11):1715-9.
Studies in which levamisole has been used with success in the treatment of rheumatoid arthritis and other autoimmune diseases may provide information useful in cancer treatment with regard to optimal dosage regimens and methods for monitoring laboratory effects. Using the response of peripheral blood lymphocytes to phytohemagglutinin mitogen measured by the uptake of tritiated thymidine in 3-day culture, patients with rheumatoid arthritis were found to have a significantly deficient response compared to normal subjects. Levamisole treatment reversed this deficiency and normalized lymphocyte mitogen responses. These studies showed the benefit of a dose of 150 mg of levamisole compared to lower doses and also showed equal maintenance of immunocompetency with a dose of 150 mg/week compared to daily levamisole. In addition, compared to poor clinical responders, good clinical responders were shown to have a greater enhancement in mitogen response, both during the treatment period and when levamisole was added in vitro to lymphocyte culture prior to drug treatment. It was concluded that laboratory studies of lymphocyte mitogen response may contribute towards better management of patients receiving levamisole therapy.
在类风湿关节炎和其他自身免疫性疾病治疗中成功使用左旋咪唑的研究，可能会为癌症治疗提供有关最佳剂量方案和实验室效应监测方法的有用信息。通过在3天培养中测量氚标记胸腺嘧啶核苷的摄取来检测外周血淋巴细胞对植物血凝素丝裂原的反应，发现类风湿关节炎患者与正常受试者相比反应明显不足。左旋咪唑治疗逆转了这种不足并使淋巴细胞丝裂原反应恢复正常。这些研究表明，与较低剂量相比，150毫克左旋咪唑剂量有益，并且与每日服用左旋咪唑相比，每周150毫克剂量也能同等维持免疫能力。此外，与临床反应不佳者相比，临床反应良好者在治疗期间以及在药物治疗前将左旋咪唑体外添加到淋巴细胞培养物中时，丝裂原反应增强更大。得出的结论是，淋巴细胞丝裂原反应的实验室研究可能有助于更好地管理接受左旋咪唑治疗的患者。
